Griggs J, Hesketh R, Smith G A, Brindle K M, Metcalfe J C, Thomas G A, Williams E D
Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge CB2 1QW, UK.
Br J Cancer. 2001 Mar 23;84(6):832-5. doi: 10.1054/bjoc.2000.1653.
Combretastatin-A4 phosphate (cis-CA-4) is a tubulin-binding agent currently undergoing clinical trials as an anti-tumour drug. We have investigated whether CA-4 functions as a tumour-specific anti-vascular agent using the hyperplastic thyroid as a novel in vivo model of neovascularization. CA-4 elicited pathological changes in normal tissue, manifested as the induction of multiple, discrete intravascular thrombi. These vascular-damaging effects indicate that CA-4P does not function as a tumour-specific agent but targets neovasculature irrespective of the primary angiogenic stimulus.
磷酸考布他汀 - A4（顺式 - CA - 4）是一种微管结合剂，目前正作为一种抗肿瘤药物进行临床试验。我们利用增生性甲状腺作为新生血管形成的新型体内模型，研究了CA - 4是否作为一种肿瘤特异性抗血管生成剂发挥作用。CA - 4在正常组织中引发了病理变化，表现为多个离散的血管内血栓形成。这些血管损伤效应表明，CA - 4P并非作为一种肿瘤特异性药物发挥作用，而是不论主要血管生成刺激因素如何，均靶向新生血管。
